{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:33:49Z","timestamp":1792524829634,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008016","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T00:00:00Z","timestamp":1337126400000}}],"reference-count":245,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008016.pub2","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T20:20:46Z","timestamp":1336681246000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Maintenance treatment with antipsychotic drugs for schizophrenia"],"prefix":"10.1002","author":[{"given":"Stefan","family":"Leucht","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdolna","family":"Tardy","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen, Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychosomatische und Medizin und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; M\u00f6hlstr. 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Davis","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago; 1601 West Taylor St Chicago USA IL 60612"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"key":"10.1002\/14651858.CD008016.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1192\/bjp.128.5.451","article-title":"A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients","volume":"128","author":"Andrews","year":"1976","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-200209000-00001","article-title":"A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg\/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study","volume":"17","author":"Arato","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0003|cit3","first-page":"330","article-title":"Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. A controlled double-blind study","volume":"10","author":"Baro","year":"1970","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","article-title":"A double-blind, randomised, placebo-controlled trial of olanzapine in the prevention of psychotic relapse","volume":"23","author":"Beasley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.jcp.0000195109.01898.5e","article-title":"Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?","volume":"26","author":"Beasley","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S0924-977X(03)92098-0","article-title":"The effectiveness of olanzapine versus placebo in maintaining the quality of life in stabilized patients with schizophrenia","volume":"13","author":"Beasley","year":"2003","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00005053-196110000-00005","article-title":"Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics","volume":"133","author":"Blackburn","year":"1981","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0009|cit8","unstructured":"Boonstra G Schizophrenia termination of pharmacotherapy-STOP-trial Current Controlled Trials 2005"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub2-BIB0008|cit9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/13651501.2010.534801","article-title":"Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial","volume":"15","author":"Boonstra","year":"2011","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0021-9681(64)90075-X","article-title":"Discontinuation or reduction of chemotherapy in chronic schizophrenics","volume":"17","author":"Caffey","year":"1964","journal-title":"Journal of Chronic Diseases"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.120.6.578","article-title":"Phenothiazine excretion in chronic schizophrenics","volume":"120","author":"Caffey","year":"1963","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0012|cit12","first-page":"333","article-title":"Penfluridol maintenance therapy in schizophrenia: a controlled study","volume":"29","author":"Channabasavanna","year":"1987","journal-title":"Indian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2007.12.020","article-title":"A double-blind randomised placebo-controlled study of relapse prevention in remitted first-episode psychosis patients following one year of maintenance therapy","volume":"98","author":"Chen","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"c4024","DOI":"10.1136\/bmj.c4024","article-title":"Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial","volume":"341","author":"Chen","year":"2010","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1192\/bjp.138.6.490","article-title":"Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?","volume":"138","author":"Cheung","year":"1981","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0016|cit16","first-page":"137","article-title":"Pimozide in chronic schizophrenic outpatients","volume":"36","author":"Clark","year":"1975","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0017|cit17","unstructured":"Cooper SJ Butler A Tweed J Raniwalla J Welch C Zotepine in the prevention of relapse Proceedings of the 6th World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France 1997"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s002130000452","article-title":"Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia","volume":"150","author":"Cooper","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Cooper SJ Butler A Tweed JA Welch CP Wighton AJ Appleby P Zotepine is effective in preventing recurrence in patients with chronic schizophrenia Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80394-5"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0920-9964(00)90814-4","article-title":"Zotepine is effective in preventing recurrence in patients with chronic schizophrenia","volume":"41","author":"Cooper","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.148.2.120","article-title":"A randomised controlled trial of prophylactic neuroleptic treatment","volume":"148","author":"Crow","year":"1986","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0022|cit22","first-page":"47","article-title":"Pimozide (OrapR, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up","volume":"76","author":"Denijs","year":"1973","journal-title":"Psychiatria, Neurologia, Neurochirurgia"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0023|cit23","first-page":"374","article-title":"Double-blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics","volume":"14","author":"Dotti","year":"1979","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0025|cit24","unstructured":"Eklund K Low dose of haloperidol decanoate is effective against relapses in schizophrenia patients. A double-blind placebo controlled study Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1990 287"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0024|cit25","first-page":"S7","article-title":"Minimal effective dose and relapse - double-blind trial: haloperidol decanoate vs. placebo","volume":"14","author":"Eklund","year":"1991","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0026|cit26","first-page":"909","article-title":"Effects of neuroleptic withdrawal on the drug-induced extrapyramidal syndrome of chronic schizophrenia","volume":"104","author":"Elie","year":"1975","journal-title":"Union Medicale du Canada"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0027|cit27","first-page":"522","article-title":"Prolonged withdrawal of chlorpromazine in chronic patients","volume":"23","author":"Freeman","year":"1962","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1176\/ajp.131.6.699","article-title":"Penfluridol: an efficacious long-acting oral antipsychotic compound","volume":"131","author":"Gallant","year":"1974","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archpsyc.1983.01790220020003","article-title":"Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures","volume":"41","author":"Gardos","year":"1984","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0030|cit30","first-page":"321","article-title":"Withdrawal of ataractic medication in schizophrenic patients","volume":"27","author":"Garfield","year":"1966","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00004714-198802000-00010","article-title":"Persistence of fluphenazine in plasma after decanoate withdrawal","volume":"8","author":"Gitlin","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0032|cit32","first-page":"116","article-title":"The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics","volume":"17","author":"Goldberg","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-198105000-00005","article-title":"Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics","volume":"1","author":"Shenoy","year":"1981","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1176\/ajp.116.10.931","article-title":"Discontinuation of treatment with ataractic drugs. A preliminary report","volume":"116","author":"Gross","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0035|cit35","first-page":"696","article-title":"A double-blind comparison of once-a-day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients","volume":"16","author":"Gross","year":"1974","journal-title":"Current Therapeutic Research"},{"issue":"554","key":"10.1002\/14651858.CD008016.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1192\/bjp.120.554.41","article-title":"Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy","volume":"120","author":"Hershon","year":"1972","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S0033291700048480","article-title":"Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community","volume":"3","author":"Stevens","year":"1973","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archpsyc.1960.01710060089013","article-title":"Denial of illness in schizophrenic outpatients: effects of psychopharmacological treatment","volume":"3","author":"Hankoff","year":"1960","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.1.5854.633","article-title":"Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry","volume":"1","author":"Hirsch","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0041|cit40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0920-9964(93)90613-N","article-title":"The effect of life events and medication in the aetiology of schizophrenic relapse","volume":"9","author":"Hirsch","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0040|cit41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/bjp.168.1.49","article-title":"A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse","volume":"168","author":"Hirsch","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archpsyc.1977.01770140061008","article-title":"Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy","volume":"34","author":"Goldberg","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0045|cit43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archpsyc.1973.01750310038007","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates","volume":"28","author":"Hogarty","year":"1973","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.1974.01760170011002","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients","volume":"31","author":"Hogarty","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0043|cit45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.1974.01760170005001","article-title":"Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates","volume":"31","author":"Hogarty","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00004714-198402000-00003","article-title":"Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate","volume":"4","author":"Hogarty","year":"1984","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archpsyc.1979.01780120013001","article-title":"Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride","volume":"36","author":"Hogarty","year":"1979","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/archpsyc.1977.01770150055005","article-title":"Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients","volume":"34","author":"Hogarty","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0049|cit49","unstructured":"Hough D Gopal S Vijapukar U Lim P Morozova M Eerdekens M Paliperidone palmitate in prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8, Washington DC, USA 2008"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0165-1781(79)90016-7","article-title":"Low dose fluphenazine decanoate in maintenance treatment of schizophrenia","volume":"1","author":"Kane","year":"1979","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archpsyc.1982.04290010048009","article-title":"Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia","volume":"39","author":"Kane","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0053|cit53","first-page":"20","article-title":"Low-dose neuroleptics in outpatient schizophrenics","volume":"18","author":"Kane","year":"1982","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0033-3182(68)71862-4","article-title":"Maintenance treatment of schizophrenic outpatients with a depot phenothiazine","volume":"9","author":"Keskiner","year":"1968","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archpsyc.1968.01740040093012","article-title":"Long-acting phenothiazine (fluphenazine decanoate) treatment of psychosis","volume":"18","author":"Keskiner","year":"1968","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/026988119000400206","article-title":"Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients","volume":"4","author":"King","year":"1990","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0057|cit57","first-page":"66","article-title":"A controlled study of a very long-acting phenothiazine preparation","volume":"1","author":"Kinross-Wright","year":"1965","journal-title":"International Journal of Neuropsychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0060|cit59","first-page":"12","article-title":"Penfluridol: once-a-week oral maintenance neuroleptic in the management of chronic schizophrenics","volume":"11","author":"Kurland","year":"1975","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0059|cit60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/j.1552-4604.1975.tb02380.x","article-title":"Penfluridol: a long-acting oral neuroleptic. A controlled study","volume":"15","author":"Kurland","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1192\/bjp.123.6.659","article-title":"Life events and maintenance therapy in schizophrenic relapse","volume":"123","author":"Leff","year":"1973","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bmj.3.5775.599","article-title":"Trial of maintenance therapy in schizophrenia","volume":"3","author":"Leff","year":"1971","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/ajp.136.2.217","article-title":"Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate","volume":"136","author":"Gelenberg","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0064|cit64","first-page":"483","article-title":"Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study","volume":"24","author":"Levine","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archpsyc.1982.04290020051010","article-title":"Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics","volume":"39","author":"Mandel","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0070|cit66","first-page":"29","article-title":"Dosage and side effect comparisons between oral and depot fluphenazine","volume":"13","author":"Schooler","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0066|cit67","first-page":"159","article-title":"The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparison between oral and depot fluphenazine","volume":"1976","author":"Schooler","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0067|cit68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0041-1723921","article-title":"The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine","volume":"9","author":"Schooler","year":"1976","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0069|cit69","first-page":"44","article-title":"Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen","volume":"15","author":"Schooler","year":"1979","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0068|cit70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/archpsyc.1980.01780140018002","article-title":"Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate","volume":"37","author":"Schooler","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/070674376400900404","article-title":"Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients","volume":"9","author":"Marjerrison","year":"1964","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0447.1989.tb03032.x","article-title":"The Scottish first episode schizophrenia study","volume":"80","author":"McCreadie","year":"1989","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/070674376601100507","article-title":"Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic in-patients","volume":"11","author":"Melnyk","year":"1966","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1176\/ajp.124.11.1585","article-title":"A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia","volume":"124","author":"Morton","year":"1968","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00432759","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenia","volume":"77","author":"Nishikawa","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00427763","article-title":"Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose response study of haloperidol and propericiazine","volume":"82","author":"Nishikawa","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0077|cit77","first-page":"195","article-title":"Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients","volume":"43","author":"Odejide","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/00005053-196202000-00005","article-title":"Intermittent chemotherapy for chronic psychiatric inpatients","volume":"134","author":"Olson","year":"1962","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005053-196009000-00007","article-title":"Sudden removal of tranquilizing drugs from chronic psychiatric patients","volume":"131","author":"Olson","year":"1960","journal-title":"Journal of Mental and Nervous Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0080|cit80","first-page":"99","article-title":"A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia","volume":"13","author":"Ota","year":"1973","journal-title":"Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008016.pub2-BIB0081|cit81","first-page":"34","article-title":"Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomised, placebo-controlled trial in clinically stable patients","volume":"4","author":"Peuskens","year":"2007","journal-title":"Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0082|cit82","article-title":"Multicentre double-blind study of ziprasidone versus placebo in relapse prevention for hospitalised patients with chronic or subchronic schizophrenia","author":"Pfizer","journal-title":"Study report."},{"key":"10.1002\/14651858.CD008016.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/S0007125000292416","article-title":"Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?","volume":"163","author":"Gaebel","year":"1993","journal-title":"British Journal of Psychiatry Supplementum"},{"issue":"1-2","key":"10.1002\/14651858.CD008016.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-9964(01)00182-7","article-title":"First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies","volume":"53","author":"Gaebel","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0085|cit85","unstructured":"Gaebel W Moeller HJ Treatment strategies in first episode schizophrenia Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0022-3956(93)90059-B","article-title":"Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study","volume":"27","author":"Pietzcker","year":"1993","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1055\/s-2007-1017177","article-title":"A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Preliminary report","volume":"19","author":"Pietzcker","year":"1986","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":"Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study","volume":"64","author":"Pigott","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0089|cit89","first-page":"983","article-title":"A 12-year follow-up study of chronic schizophrenics","volume":"33","author":"Gardos","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0091|cit90","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archpsyc.1968.01740040098013","article-title":"High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group","volume":"18","author":"Prien","year":"1968","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0090|cit91","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1192\/bjp.115.523.679","article-title":"Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication","volume":"115","author":"Prien","year":"1968","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archpsyc.1970.01750050080011","article-title":"Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study","volume":"23","author":"Prien","year":"1970","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0093|cit93","first-page":"739","article-title":"Indications for high dose chlorpromazine therapy in chronic schizophrenia","volume":"31","author":"Prien","year":"1970","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1176\/ajp.126.3.305","article-title":"High dose trifluoperazine therapy in chronic schizophrenia","volume":"126","author":"Prien","year":"1969","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0096|cit95","first-page":"40","article-title":"Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data","volume":"13","author":"Rifkin","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0095|cit96","first-page":"499","article-title":"The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics","volume":"14","author":"Rifkin","year":"1979","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0097|cit97","first-page":"15","article-title":"Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data","volume":"34","author":"Rifkin","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0098|cit98","first-page":"24","article-title":"Comparison of fluphenazine decanoate, oral fluphenazine, and placebo in remitted outpatient schizophrenics","volume":"12","author":"Rifkin","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1977.01770130045004","article-title":"Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year","volume":"34","author":"Rifkin","year":"1977","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-0447.1974.tb08210.x","article-title":"Penfluridol (R 16341) as a maintenance therapy in chronic psychotic patients: a double-blind clinical evaluation","volume":"50","author":"Roelofs","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005053-199104000-00006","article-title":"Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial","volume":"179","author":"Ruskin","year":"1991","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hup.470070405","article-title":"Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neuroleptic levels","volume":"7","author":"Sampath","year":"1992","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.470050308","article-title":"Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment","volume":"5","author":"Soni","year":"1990","journal-title":"Human Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008016.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4088\/JCP.10m06306","article-title":"A randomised placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment","volume":"72","author":"Kane","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0105|cit105","first-page":"151","article-title":"A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients","volume":"22","author":"Schiele","year":"1961","journal-title":"Journal of Clinical and Experimental Psychopathology and Quarterly Review of Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0106|cit106","first-page":"452","article-title":"Comparison of chlorpromazine and reserpine in maintenance drug therapy","volume":"20","author":"Shawver","year":"1959","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/schbul\/12.3.394","article-title":"Episodic and residual thought pathology in chronic schizophrenics: effect of neuroleptics","volume":"12","author":"Spohn","year":"1986","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0108|cit108","first-page":"11","article-title":"Maintenance phenothiazines in aftercare of schizophrenic patients","volume":"2","author":"Troshinsky","year":"1962","journal-title":"Pennsylvania Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1974.tb08220.x","article-title":"A double-blind clinical evaluation of penfluridol (R 16 341) as a maintenance therapy in schizophrenia","volume":"50","author":"Vandecasteele","year":"1974","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1192\/bjp.109.460.422","article-title":"Withdrawal of perphenazine in chronic schizophrenia","volume":"109","author":"Whittaker","year":"1963","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0115|cit111","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1981.tb00761.x","article-title":"A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients","volume":"64","author":"Wistedt","year":"1981","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0116|cit112","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/archpsyc.1982.04290060085019","article-title":"Neuroleptics and depression","volume":"39","author":"Wistedt","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0111|cit113","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0112|cit114","first-page":"369","article-title":"Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics","volume":"44","author":"Wistedt","year":"1983","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0113|cit115","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0447.1983.tb09718.x","article-title":"Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology","volume":"67","author":"Wistedt","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0114|cit116","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00427950","article-title":"A depot neuroleptic withdrawal study neurological effects","volume":"80","author":"Wistedt","year":"1983","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0117|cit117","first-page":"650","article-title":"Haloperidol decanoate, a new long-acting antipsychotic, in chronic schizophrenics: double-blind comparison with placebo","volume":"31","author":"Zissis","year":"1982","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0118|cit118","unstructured":"Allen DN Gilbertson MW Barry E Kammen DP Gurklis JA Haloperidol improves memory in schizophrenia Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.12.371","article-title":"Efficacy of bifeprunox in patients in the post-acute, maintenance phase of schizophrenia: findings from a 6-month study","volume":"98","author":"Bourin","year":"2008","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0120|cit120","first-page":"118","article-title":"Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia","volume":"17","author":"Branchey","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1176\/ajp.138.5.608","article-title":"Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients","volume":"138","author":"Branchey","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1176\/ajp.144.12.1549","article-title":"Neuroleptic responsivity of negative and positive symptoms in schizophrenia","volume":"144","author":"Breier","year":"1987","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0447.1981.tb00794.x","article-title":"Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system","volume":"64","author":"Chouinard","year":"1980","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archpsyc.1974.01760150069010","article-title":"Group therapy and maintenance treatment of schizophrenics","volume":"31","author":"Claghorn","year":"1974","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1192\/bjp.113.505.1425","article-title":"A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics","volume":"113","author":"Collins","year":"1967","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0006-3223(95)00378-T","article-title":"Language comprehension in schizophrenia: trait or state indicator?","volume":"38","author":"Condray","year":"1995","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1192\/bjp.146.5.469","article-title":"Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine\/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.146.5.464","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine- placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1192\/bjp.146.5.474","article-title":"Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008016.pub2-BIB0130|cit130","first-page":"890","article-title":"Time relationship between the appearance of persisting extrapyramidal hyperkineses and psychotic recurrences following sudden interruption of prolonged neuroleptic therapy of chronic schizophrenic patients","volume":"20","author":"Degkwitz","year":"1970","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005053-196009000-00006","article-title":"Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage","volume":"131","author":"Diamond","year":"1960","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0447.1993.tb03477.x","article-title":"Efficacy of maintenance use of anticholinergic agents","volume":"88","author":"Double","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0133|cit133","first-page":"32","article-title":"Effects of ethopropazine and trihexyphenidyl on several parameters of the neuroleptic syndrome","volume":"61","author":"Elie","year":"1972","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1967.01730190100013","article-title":"Phenothiazines in prevention of psychiatric hospitalisation","volume":"16","author":"Engelhardt","year":"1967","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0135|cit135","first-page":"61","article-title":"Episode ii: prevention of relapse following early psychosis","volume":"70","author":"Gleeson","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00005053-196708000-00008","article-title":"Paranoid and withdrawal symptoms in schizophrenia: differential symptom reduction over time","volume":"145","author":"Goldberg","year":"1967","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005053-195808000-00009","article-title":"Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics","volume":"127","author":"Mefferd","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.115.5.443","article-title":"Termination of chlorpromazine with schizophrenic patients","volume":"115","author":"Good","year":"1958","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/ajp.123.2.221","article-title":"Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients","volume":"123","author":"Greenberg","year":"1966","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005053-195809000-00002","article-title":"Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic","volume":"127","author":"Hine","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1192\/bjp.113.505.1419","article-title":"A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics","volume":"113","author":"Hunt","year":"1967","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0142|cit142","first-page":"33","article-title":"Penfluridol in the maintenance therapy of schizophrenia","volume":"21","author":"Ionescu","year":"1983","journal-title":"Neurologie et Psychiatrie"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0143|cit143","first-page":"608","article-title":"The effects of withdrawal of trifluoperazine on patients maintained on the combination of tranylcypromine and trifluoperazine: a double-blind study","volume":"85","author":"Janecek","year":"1963","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(88)90682-4","article-title":"The Northwick Park \"functional\" psychosis study: diagnosis and treatment response","volume":"2","author":"Johnstone","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/026988119100500433","article-title":"The Northwick Park 'functional' psychosis study. Phase 2 - maintenance treatment","volume":"5","author":"Johnstone","year":"1991","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0146|cit146","unstructured":"Johnstone EC Owens DGC Does early treatment have an effect on outcome? Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0447.1971.tb02203.x","article-title":"A double-blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy","volume":"47","author":"Kellam","year":"1971","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.schres.2004.05.006","article-title":"Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia","volume":"72","author":"Lauriello","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0149|cit149","unstructured":"Lecrubier Y Amisulpride in deficit schizophrenia Proceedings of the 6th World Congress Biological Psychiatry, 1997 Jun 22-27; Nice, France 1997"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia","volume":"170","author":"Loo","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00005053-195808000-00009","article-title":"Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics","volume":"127","author":"Mefferd","year":"1958","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.NMD.0000061148.84257.F9","article-title":"Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project","volume":"191","author":"Bola","year":"2003","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/schbul\/5.2.322","article-title":"A non neuroleptic treatment for schizophrenia: analysis of the two year postdischarge risk of relapse","volume":"5","author":"Matthews","year":"1979","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1939-0025.1975.tb02556.x","article-title":"Soteria: evaluation of a home-based treatment for schizophrenia","volume":"45","author":"Mosher","year":"1975","journal-title":"American Journal of Orthopsychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0155|cit155","first-page":"715","article-title":"Community residential treatment for schizophrenia: two year follow up","volume":"29","author":"Mosher","year":"1978","journal-title":"Hospital and Community Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0156|cit156","first-page":"1","article-title":"To prevent relapse of schizophrenic psychoses","volume":"14","author":"M\u00fcller","year":"1982","journal-title":"Ferdinand Enke Verlag Stuttgart"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/archpsyc.1972.01750250092013","article-title":"Maintenance psychotropic drugs in the presence of active treatment programs. A \"triple-blind\" withdrawal study with long-term mental patients","volume":"27","author":"Paul","year":"1972","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1192\/bjp.139.2.112","article-title":"Propranolol in schizophrenia II. Clinical and biochemical aspects of combining propranolol with chlorpromazine","volume":"138","author":"Peet","year":"1981","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archpsyc.1986.01800070059008","article-title":"Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment","volume":"43","author":"Pickar","year":"1986","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1176\/appi.ajp.160.6.1133","article-title":"Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia","volume":"160","author":"Pickar","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0163|cit161","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0920-9964(93)90076-U","article-title":"Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study","volume":"10","author":"Pigache","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0164|cit162","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0920-9964(93)90075-T","article-title":"The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia with placebo substitution for chlorpromazine","volume":"10","author":"Pigache","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0161|cit163","doi-asserted-by":"crossref","first-page":"28P","DOI":"10.1042\/cs044028Pa","article-title":"Measurement of drug action in schizophrenia","volume":"44","author":"Pigache","year":"1973","journal-title":"Clinical Science"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0162|cit164","first-page":"160","article-title":"Selective attention as an index of the anti-psychotic action of chlorpromazine in schizophrenia","volume":"20","author":"Pigache","year":"1973","journal-title":"British Psychological Society Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub2-BIB0165|cit165","first-page":"216","article-title":"Withdrawal of antipsychotic drugs from chronic psychiatric patients","volume":"34","author":"Rassidakis","year":"1970","journal-title":"Bulletin of the Menninger Clinic"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0166|cit166","first-page":"33","article-title":"A controlled study of fluphenazine enanthate in chronic schizophrenic patients","volume":"25","author":"Ravaris","year":"1965","journal-title":"Diseases of the Nervous System"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1176\/ajp.124.2.248","article-title":"Further studies with fluphenazine enanthate: II. Relapse rate in patients deprived of medication","volume":"124","author":"Ravaris","year":"1967","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD008016.pub2-BIB0168|cit168","first-page":"642","article-title":"A comparative controlled study of two long-acting phenothiazines: pipotiazine palmitate and fluphenazine decanoate","volume":"23","author":"Schlossberg","year":"1978","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0169|cit169","first-page":"319","article-title":"Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis","volume":"51","author":"Singh","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/01.jcp.0000245562.99036.92","article-title":"Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use","volume":"26","author":"Smelson","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.470050308","article-title":"Sulpiride in negative schizophrenia: a placebo-controlled double-blind assessment","volume":"5","author":"Soni","year":"1990","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0172|cit172","first-page":"277","article-title":"A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo","volume":"36","author":"Dellva","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00004714-199910000-00007","article-title":"Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo","volume":"19","author":"Tollefson","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0174|cit174","doi-asserted-by":"crossref","unstructured":"Tollefson GD Dellva MA Mattler CA Kinon BJ Grundy SL A controlled, double-blind investigation of the clozapine discontinuation syndrome with conversion to either olanzapine or placebo Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80386-6"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF00180839","article-title":"A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients","volume":"88","author":"Vaddadi","year":"1986","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1176\/ajp.139.8.991","article-title":"D-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia","volume":"139","author":"Kammen","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0177|cit177","first-page":"655","article-title":"Amphetamine-induced catecholamine activation in schizophrenia and depression: behavioral and physiological effects","volume":"16","author":"Kammen","year":"1977","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/archpsyc.1980.01780160057006","article-title":"Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients","volume":"37","author":"Kammen","year":"1980","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/0024-3205(78)90130-3","article-title":"D amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment","volume":"23","author":"Kammen","year":"1978","journal-title":"Life Sciences"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1176\/ajp.130.7.801","article-title":"Fluphenazine enanthate and fluphenazine decanoate: a comparison of their duration of action and motor side effects","volume":"130","author":"Praak","year":"1973","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s004060170056","article-title":"Effectiveness of targeted intervention and maintenance pharmacotherapy in conjunction with family intervention in schizophrenia","volume":"251","author":"Wiedemann","year":"2001","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/070674376400900411","article-title":"Value of continuous drug administration for chronic long-term mental hospital patients","volume":"60","author":"Wright","year":"1964","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0920-9964(06)70152-9","article-title":"Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome","volume":"86","author":"Wunderink","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.1956.02960380027008","article-title":"Use of chlorpromazine and reserpine in the treatment of emotional disorders","volume":"160","author":"Zeller","year":"1956","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0185|cit185","first-page":"83","article-title":"Penfluridol (R 16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients","volume":"76","author":"Zwanikken","year":"1973","journal-title":"Psychiatria, Neurologia, Neurochirurgia"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0186|cit186","unstructured":"Eerdekens Evaluate the efficacy in the prevention of recurrence of the symptoms of schizophrenia Sponsor: Johnson & Johnson Pharmaceutical Research & Development, LL.C 2010"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub2-BIB0187|cit187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0189|cit189","volume-title":"Chemotherapy in psychiatry: principles and practice","author":"Baldessarini","year":"1985"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0191|cit191","volume-title":"Psychische Erkrankungen. Klinik und Therapie","author":"Berger","year":"2003"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD008016.pub2-BIB0193|cit193","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0194|cit194","unstructured":"Borenstein M Hedges LV Higgins JPT Rothstein H Comprehensive Meta-analysis Version 2 2006"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008016.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1176\/ajp.132.12.1237","article-title":"Overview: maintenance therapy in psychiatry: I. Schizophrenia","volume":"132","author":"Davis","year":"1975","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0197|cit197","first-page":"1591","article-title":"Antipsychotic drugs","volume-title":"Comprehensive Textbook of Psychiatry","author":"Davis","year":"1989"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0198|cit198","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub2-BIB0201|cit201","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD008016.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","article-title":"Neuroleptic withdrawal in schizophrenic patients. A review of the literature","volume":"52","author":"Gilbert","year":"1995","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0208|cit208","volume-title":"ECDEU assessment manual for psychopharmacology-revised 1976. Washington, DC: DHEW","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0209|cit209","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0211|cit211","volume-title":"Positive And Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1017\/S0033291700046377","article-title":"A self-rating scale of distress","volume":"3","author":"Kellner","year":"1973","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0213|cit213","unstructured":"Kishimoto T Robenzadeh A Leucht C Leucht S Watanabe K Mimura M New results alter balance of evidence of long-acting injectable vs. oral antipsychotics regarding relapse prevention in schizophrenia: a systematic review and meta-analysis in press"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0214|cit214","volume-title":"Diagnosis and Drug Treatment of Psychiatric Disorders","author":"Klein","year":"1969"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomised controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomised, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD008016.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head to head comparisons of second generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Molecular Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment? A review","volume":"39","author":"Marwaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"285","author":"Moher","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","article-title":"Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse","volume":"114","author":"Moncrieff","year":"2006","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1176\/appi.ajp.161.9.1692","article-title":"Safety reporting in randomised trials of mental health interventions","volume":"161","author":"Papanikolaou","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1192\/bjp.bp.109.070961","article-title":"Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used","volume":"197","author":"Pope","year":"2010","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub2-BIB0235|cit235","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0236|cit236","unstructured":"Stata Corporation Intercooled Stata 7.0 for Windows 2002"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archpsyc.1997.01830130055011","article-title":"Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment","volume":"54","author":"Viguera","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008016.pub2-BIB0240|cit240","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059","article-title":"Clozapine vs typical neuroleptic medication for schizophrenia","author":"Wahlbeck","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1192\/bjp.180.6.490","article-title":"Violence and schizophrenia: examining the evidence","volume":"180","author":"Walsh","year":"2002","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008016.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","article-title":"Influence of antipsychotics on mortality in schizophrenia: systematic review","volume":"113","author":"Weinmann","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.177.1.42","article-title":"Self-report quality of life measure for people with schizophrenia: the SQLS","volume":"177","author":"Wilkinson","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008016.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"key":"10.1002\/14651858.CD008016.pub2-BIB0245|cit245","unstructured":"Leucht S Tardy M Komossa K Heres S Kissling W Salanti G Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: systematic review and meta-analysis Lancet"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008016.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008016.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T11:06:28Z","timestamp":1642244788000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008016.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,16]]},"references-count":245,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008016.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008016.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,16]]}}}